Technical Indicators Signal Bullish Momentum
The primary catalyst for the upgrade stems from a marked improvement in Ajanta Pharma’s technical grade, which shifted from mildly bullish to bullish. Key momentum indicators underpin this positive outlook. The Moving Average Convergence Divergence (MACD) remains bullish on both weekly and monthly charts, confirming sustained upward momentum. Meanwhile, the Relative Strength Index (RSI) on weekly and monthly timeframes shows a neutral stance, indicating no immediate overbought or oversold conditions, which supports a stable bullish trend.
Bollinger Bands also reflect a mildly bullish posture on weekly and monthly scales, suggesting moderate volatility with a positive bias. Daily moving averages reinforce this trend, showing consistent upward price movement. The Know Sure Thing (KST) indicator is bullish weekly but mildly bearish monthly, signalling some caution over longer-term momentum. On-balance volume (OBV) is bullish monthly, indicating accumulation by investors, although weekly OBV shows no clear trend. Dow Theory analysis remains neutral, with no definitive trend signals on weekly or monthly charts.
Despite a slight day decline of 1.27% to ₹2,953.00 on 10 March 2026, the technical landscape overall favours a bullish outlook, justifying the upgrade in technical grade and contributing significantly to the overall Mojo Grade improvement from Hold to Buy.
Valuation Remains Premium but Justified by Quality
Ajanta Pharma’s valuation metrics present a mixed picture. The company trades at a Price to Book (P/B) ratio of 8.6, which is expensive relative to its peers and historical averages. This premium valuation is supported by a robust Return on Equity (ROE) of 21.01%, reflecting efficient capital utilisation and strong profitability. However, the Price/Earnings to Growth (PEG) ratio stands at 2.8, indicating that the stock’s price growth outpaces earnings growth, which may concern value-focused investors.
While the elevated valuation suggests limited margin for error, the company’s consistent outperformance relative to the broader market provides some comfort. Over the past year, Ajanta Pharma has delivered a 15.78% return compared to the Sensex’s 4.35%, and over three and five years, the stock has generated returns of 140.35% and 151.23% respectively, far exceeding the Sensex’s 29.70% and 52.01% gains. This strong relative performance supports the premium valuation and the Buy rating.
Our latest weekly pick is live! This Large Cap from Diamond & Gold Jewellery comes with clear entry and exit targets. See the detailed report with target price now!
- - Clear entry/exit targets
- - Target price revealed
- - Detailed report available
Financial Trend Shows Strong Quarterly Performance
Ajanta Pharma’s financial trend remains robust, with the company reporting its highest quarterly figures in Q3 FY25-26. Net sales reached ₹1,374.84 crores, PBDIT surged to ₹382.24 crores, and Profit Before Tax excluding other income stood at ₹333.63 crores, all marking record highs. These figures underscore the company’s operational strength and growth trajectory.
Management efficiency is reflected in the high ROE of 21.01%, while the company maintains a conservative capital structure with an average Debt to Equity ratio of zero, indicating no reliance on debt financing. Institutional holdings are substantial at 26.56%, signalling confidence from sophisticated investors who typically conduct rigorous fundamental analysis before committing capital.
Despite these positives, some caution is warranted as the company’s operating profit has grown at a modest compound annual growth rate (CAGR) of 8.86% over the past five years. This slower growth rate may temper expectations for rapid expansion in the near term.
Quality Assessment Highlights Strengths and Risks
Ajanta Pharma’s quality grade remains strong, supported by consistent returns and efficient management. The company has outperformed the BSE500 index in each of the last three annual periods, delivering steady value to shareholders. Its 10-year return of 214.25% closely matches the Sensex’s 212.84%, demonstrating long-term resilience.
However, the premium valuation and relatively high PEG ratio of 2.8 suggest that investors are paying for quality and growth expectations. The stock’s elevated Price to Book ratio of 8.6 and ROE of 22.6% indicate that while the company is highly profitable, it is also priced for perfection, leaving limited room for disappointment.
Investors should weigh these factors carefully, balancing the company’s strong fundamentals and technical momentum against the risks of stretched valuation and moderate profit growth.
Want to dive deeper on Ajanta Pharma Ltd.? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Comparative Performance and Market Context
Ajanta Pharma’s stock has demonstrated resilience amid broader market volatility. Over the past month, the stock gained 3.30%, outperforming the Sensex which declined by 7.73%. Year-to-date, Ajanta Pharma has returned 6.60% compared to the Sensex’s negative 8.98%. This relative strength is further emphasised by the one-week performance, where the stock’s decline of 0.39% was significantly less severe than the Sensex’s 3.33% drop.
The stock’s 52-week high stands at ₹3,052.20, with a low of ₹2,022.05, indicating a strong recovery and upward trajectory over the past year. Despite a recent dip to ₹2,856.60 intraday, the closing price of ₹2,953.00 remains close to the upper range, supporting the bullish technical outlook.
These factors collectively justify the upgrade to a Buy rating, reflecting confidence in Ajanta Pharma’s ability to sustain growth and deliver shareholder value in the medium term.
Risks and Considerations
While the upgrade is well supported, investors should remain mindful of certain risks. The company’s operating profit growth rate of 8.86% over five years is moderate, potentially limiting upside in earnings acceleration. The premium valuation metrics, including a high P/B ratio and PEG ratio, imply that the stock is priced for continued strong performance, which may not materialise if market conditions deteriorate or growth slows.
Additionally, the mixed signals from some technical indicators, such as the mildly bearish monthly KST and neutral Dow Theory trends, suggest that investors should monitor momentum closely for any signs of reversal.
Overall, the upgrade to Buy by MarketsMOJO, with a Mojo Score of 72.0, reflects a balanced assessment of Ajanta Pharma’s strengths and risks, favouring a positive investment stance supported by strong technicals, solid financials, and quality management.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
